Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burdenRahel Schwotzer, B. Gerber, Sofie Brouwers et al.|Hematological Oncology|2019Cited by 34
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry studyB. Gerber, Guido Ghilardi, Thomas Pabst et al.|Bone Marrow Transplantation|2018Cited by 20
Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14)Guido Ghilardi, B. Gerber, Georg Stüssi et al.|Amyloid|2019Cited by 19
Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 TrialRathana Kim, Emmanuelle Clappier, Philippe Rousselot et al.|Blood|2021Cited by 9